ArticleAnnals of hematology2023

Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials.

Luigia Luciano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.